Citation

Hanna N, Karabelnik L, Ranga J. Conn. Med. 2005; 69(9): 541-546.

Affiliation

Child and Adolescent Psychiatry, Institute of Living/Hartford Hospital, Hartford, USA.

Copyright

(Copyright © 2005, Connecticut State Medical Society)

DOI

unavailable

PMID

16270791

Abstract

The controversy surrounding the use of Selective Serotonin Reuptake Inhibitors (SSRIs), in the treatment of depression and other psychiatric disorders in children and adolescents, has come to the forefront since the question of increased suicidal risk has been raised. There are limited research data available to thoroughly analyze the safety and efficacy of this class of medications in youths. In this article, we review the evidence available, the events that led to the black box warning, and the practical implications of the warning for providers, youth and families.